期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Pancreatic adenocarcinoma:Beyond first line,where are we? 被引量:1
1
作者 Sara Cherri silvia noventa Alberto Zaniboni 《World Journal of Gastroenterology》 SCIE CAS 2021年第17期1847-1863,共17页
Pancreatic cancer is considered one of the most aggressive cancers,with an increasing incidence in recent years.To date,chemotherapy is still the standard of care for advanced metastatic disease,unfortunately providin... Pancreatic cancer is considered one of the most aggressive cancers,with an increasing incidence in recent years.To date,chemotherapy is still the standard of care for advanced metastatic disease,unfortunately providing only a slight advantage in terms of survival.The molecular and cellular characteristics of pancreatic cancer cells,as well as the cells that characterize the pancreatic tumour microenvironment,are the basis of the mechanisms of resistance to treatment.After progression during first-line treatment,few patients are eligible for secondline treatment due to the loss of performance status.To date,a clear survival advantage has not yet been demonstrated for second-line chemotherapy.Precision medicine could be the key to increasing responses to cancer treatment and finally impacting survival in this difficult-to-treat disease.In this review,we analyze current recommendations in the second-line setting and potential future prospects. 展开更多
关键词 Pancreatic adenocarcinoma SECOND-LINE CHEMOTHERAPY Targeted therapy IMMUNOTHERAPY
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部